Form 4: Iovance CMO's RSU Vesting and Tax Withholding

Iovance Biotherapeutics' Chief Medical Officer, Friedrich Graf Finckenstein, reported the vesting of 31,246 restricted stock units and subsequent tax withholding.

Summary

• Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, reported the vesting of 31,246 Restricted Stock Units (RSUs) on March 5, 2026.
• Upon vesting, 31,246 shares of common stock were acquired.
• 16,520 shares were withheld by the Issuer at a price of $4.58 per share to satisfy mandatory tax withholding requirements; this was not an open market sale.
• Following these transactions, Graf Finckenstein directly owns 131,957 shares of common stock.
• An aggregate of 62,504 Restricted Stock Units remain, which will vest in equal quarterly installments.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting the routine vesting of executive equity compensation and standard tax procedures, with no direct impact on company operations or financial performance beyond compensation expense.

Positives

• 31,246 Restricted Stock Units (RSUs) held by the Chief Medical Officer vested, converting into common stock.
• The vesting represents a realization of equity compensation for the Chief Medical Officer.

Negatives

• 16,520 shares of common stock were withheld by the company to cover mandatory tax obligations, reducing the net shares received by the Chief Medical Officer.

Future Outlook

The remaining 62,504 Restricted Stock Units held by the Chief Medical Officer are scheduled to vest in equal quarterly installments, indicating a continued long-term equity incentive structure.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax withholding are standard practices for executive compensation in the biotechnology and pharmaceutical industries, aligning executive incentives with long-term company performance.

Related Party Transactions

• The transaction involves the vesting of Restricted Stock Units and subsequent share withholding for taxes between the company (Iovance Biotherapeutics, Inc.) and its Chief Medical Officer, Friedrich Graf Finckenstein, which is a standard related-party compensation event.

Stakeholder Impact

• Shareholders: Minimal direct impact as RSU vesting is a routine compensation event, though it represents a slight increase in outstanding shares over time (already accounted for in dilution models).
• Employees: Reflects standard executive compensation practices, potentially signaling stability in executive incentives.

Next Steps

• The remaining 62,504 Restricted Stock Units will vest in equal quarterly installments.

Key Dates

Keywords

Iovance Biotherapeutics, IOVA, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Equity Compensation, Chief Medical Officer, Friedrich Graf Finckenstein, Tax Withholding